Sana Biotechnology, Inc. Income Statement
SANA / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| SG&A Expense | $64.0M | $73.3M | $71.6M | $50.4M | $28.3M | $21.8M |
| R&D Expense | $217.6M | $268.8M | $285.9M | $248.6M | $132.9M | $99.6M |
| Operating Income | -$272.7M | -$293.1M | -$272.6M | -$356.9M | -$286.1M | -$141.2M |
| Income Tax | - | - | - | - | - | -$7.5M |
| Net Income | -$266.8M | -$283.3M | -$269.5M | -$355.9M | -$285.3M | -$130.8M |
| EPS (Basic) | -$1.16 | -$1.46 | -$1.43 | -$2.14 | -$21.92 | - |
| EPS (Diluted) | -$1.16 | -$1.46 | -$1.43 | -$2.14 | -$21.92 | - |
| Shares Outstanding | 230.9M | 194.5M | 188.3M | 166.4M | 13.0M | 4.9M |